Fredun Pharmaceuticals Ltd

AI

Fredun Pharmaceuticals Ltd

₹ 1,636 4.10%
18 Nov - close price
About

Incorporated in 1987, Fredun Pharmaceuticals
Ltd manufactures & exports healthcare and pharmaceuticals products[1]

Key Points

Business Overview:{# https://www.bseindia.com/xml-data/corpfiling/AttachHis/2ad9e590-baf1-43e5-a921-d0d5a2e4d356.pdf#page=2#}
The company is a diversified healthcare company engaged in pharmaceuticals, nutraceuticals, cosmeceuticals, dietary supplements, and animal healthcare products. Its pharmaceutical portfolio spans multiple therapeutic areas, including antihypertensives, antidiabetics, antiretrovirals (ARVs), and narcotics.

  • Market Cap ₹ 2,803 Cr.
  • Current Price ₹ 1,636
  • High / Low ₹ 1,666 / 454
  • Stock P/E 52.9
  • Book Value ₹ 196
  • Dividend Yield 0.01 %
  • ROCE 21.3 %
  • ROE 15.6 %
  • Face Value ₹ 10.0

Pros

  • Debtor days have improved from 97.8 to 53.2 days.

Cons

  • Stock is trading at 8.37 times its book value
  • Promoter holding has decreased over last quarter: -0.95%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2023 (S) Dec 2023 (S) Mar 2024 (S) Jun 2024 (S) Sep 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
82 87 118 79 0 167 120 145 161 213 228 268
72 76 107 68 0 150 103 123 135 184 196 225
Operating Profit 10 11 11 10 0 17 17 22 26 29 33 42
OPM % 12% 12% 9% 13% 10% 14% 15% 16% 14% 14% 16%
0 0 0 0 0 0 0 0 0 0 0 0
Interest 3 4 4 4 0 8 7 8 11 14 9 9
Depreciation 1 1 1 1 0 2 1 2 2 3 4 4
Profit before tax 6 6 6 6 0 7 9 13 14 11 21 30
Tax % 32% 27% 13% 25% 17% 25% 26% 25% 4% 36% 37%
4 4 5 4 0 6 7 9 10 11 13 19
EPS in Rs 2.79 2.99 3.59 2.91 0.00 4.23 4.77 6.64 6.51 6.57 7.96 10.99
Raw PDF

(S): Standalone figures, shown where consolidated figures are not available.

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 Mar 2026 TTM
25 42 57 60 97 113 134 222 275 348 454 635 870
24 38 53 54 87 104 126 208 247 310 401 545 740
Operating Profit 2 4 3 6 10 8 8 14 28 38 52 91 130
OPM % 7% 9% 6% 10% 11% 7% 6% 6% 10% 11% 12% 14% 15%
0 1 2 0 0 1 1 2 2 1 2 4 0
Interest 1 2 2 2 3 4 4 5 9 14 22 39 42
Depreciation 1 1 1 1 1 2 2 2 3 4 5 8 12
Profit before tax 1 2 2 3 6 2 3 9 18 21 27 47 75
Tax % 52% 42% 36% 34% 28% 24% 37% 26% 38% 27% 28% 31%
0 1 1 2 4 2 2 6 11 16 20 33 53
EPS in Rs 0.37 1.51 2.01 1.70 3.72 1.58 1.68 4.77 7.95 11.08 13.90 19.89 32.03
Dividend Payout % 0% 13% 10% 12% 6% 14% 14% 5% 3% 2% 2% 1%

(S): Standalone figures, shown where consolidated figures are not available.

Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 40%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: 65%
Stock Price CAGR
10 Years: 61%
5 Years: 60%
3 Years: 78%
1 Year: 158%
Return on Equity
10 Years: %
5 Years: %
3 Years: %
Last Year: 16%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 Mar 2026 Sep 2026
Equity Capital 2 2 2 3 4 4 4 4 5 5 5 5 17
Reserves 0 1 2 19 35 37 39 64 92 117 137 273 314
9 16 21 10 19 35 40 53 87 106 167 222 253
11 24 30 47 47 65 79 66 74 81 179 142 190
Total Liabilities 23 43 56 79 105 141 162 187 257 308 487 642 774
8 15 16 16 31 31 30 32 39 47 53 118 153
CWIP 1 0 4 11 0 0 0 0 0 0 0 0 0
Investments 0 0 0 0 0 0 0 0 0 1 2 2 3
14 29 36 52 74 110 131 155 218 260 433 522 619
Total Assets 23 43 56 79 105 141 162 187 257 308 487 642 774

(S): Standalone figures, shown where consolidated figures are not available.

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 Mar 2026
2 3 4 17 1 -11 0 -2 -14 -0 -17 12
-3 -6 -7 -8 -5 -1 -1 -4 -9 -8 -6 -74
1 3 3 -8 4 14 -1 7 25 6 27 121
Net Cash Flow 0 1 -1 1 0 2 -2 1 1 -2 4 60
Free Cash Flow -1 -3 -3 9 -4 -12 -1 -7 -24 -8 -23 -62
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 108% 85% 117% 303% 8% -128% 2% -17% -52% -1% -32% 13%

(S): Standalone figures, shown where consolidated figures are not available.

Ratios

Consolidated / View Standalone

Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 (S) Mar 2025 Mar 2026
Debtor Days 75 98 131 94 67 126 112 148 46 68 142 53
Inventory Days 102 140 68 170 249 227 242 96 264 246 267 219
Days Payable 167 221 224 360 205 208 215 101 104 88 161 71
Cash Conversion Cycle 11 17 -24 -96 110 145 139 144 205 225 248 201
Working Capital Days -54 -44 -39 42 66 65 116 126 97 92 76 78
ROCE % 14% 25% 18% 16% 21% 10% 10% 13% 18% 17% 21%

(S): Standalone figures, shown where consolidated figures are not available.

Insights

In beta
Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Capsules Capacity
millions per day ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Granulation Capacity
kgs per day ・Standalone data
Tablet Compression Capacity
millions per day ・Standalone data
Countries with Product Registration / Export Presence
countries ・Standalone data
Cumulative Registered Products (Final Registrations)
products ・Standalone data
Products Under Registration (Pipeline)
products ・Standalone data
Contract / Third-Party Manufacturing Locations
locations ・Standalone data
Total SKUs (Stock Keeping Units)
SKUs ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
49.16% 49.17% 49.17% 48.93% 48.93% 48.93% 48.93% 48.93% 43.06% 44.17% 44.57% 43.62%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.01% 0.46% 1.06% 1.06% 0.69%
1.60% 1.60% 1.60% 1.59% 1.59% 1.59% 1.59% 1.61% 3.48% 2.83% 2.94% 3.43%
49.24% 49.24% 49.23% 49.47% 49.47% 49.47% 49.49% 49.46% 53.00% 51.94% 51.45% 52.25%
No. of Shareholders 6,8377,5077,5118,0188,1217,9767,9068,1208,7658,3388,90313,502

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Concalls